Exubrion
1 known investors
Exubrion Therapeutics develops veterinary therapies using conversion electron therapy from Tin-117m to treat pain and inflammation in companion animals. Its initial product, Synovetin OA, is a minimally invasive intra-articular injection for canine elbow osteoarthritis, marketed to veterinarians and pet owners.
Investors Β· 1
Frequently asked questions
- What does Exubrion do?
- Exubrion Therapeutics develops veterinary therapies using conversion electron therapy from Tin-117m to treat pain and inflammation in companion animals. Its initial product, Synovetin OA, is a minimally invasive intra-articular injection for canine elbow osteoarthritis, marketed to veterinarians and pet owners.
- Who are Exubrion's investors?
- Exubrion's investors include Mountain Group Capital.